Genetic Testing Market size is set to exceed USD 31.8 billion by 2027, according to a new research report by Global Market Insights Inc. Increasing application of genetic testing in oncology and genetic diseases coupled with growing adoption of genetic tests into clinical care will drive the market growth.
Rising awareness regarding personalized medication
Personalized medicines offer specialized treatments to patients based on molecular basis of a disease. Genome sequencing and genetic testing can be used to determine molecular basis of a disease. Therefore, people in developed countries including the U.S. and European countries are screened for various genetic and rare diseases. Early detection of these diseases helps to minimize the severity and can prevent the onset of symptoms proving effective for patient management.
Moreover, personalization of treatment may avoid possible risks in the future by offering an array of diagnostic techniques enabling people to take precautionary steps. Also, biopharmaceutical researchers project an increase in the number of personalized medicines over analysis timeline due to its effective nature in curing patients with better results than the commercially available medications.
Rising demand for prenatal and newborn screening in genetic testing
Get more details on this report - Request Free Sample PDF
The prenatal and newborn testing segment held around 30% market share in 2020, owing to increasing importance of newborn and prenatal screening in developed economies. The prenatal tests are usually taken during pregnancy to determine the likelihood of a baby having any birth defects. Most of the tests are noninvasive and are performed during first or second trimester proving beneficial for the segment growth. Moreover, surging significance of prenatal screening to determine chromosomal abnormalities or health condition such as down syndrome in babies will fuel the market expansion.
Browse key industry insights spread across 200 pages with 138 market data tables & 07 figures & charts from the report, “Genetic Testing Market Size By Test Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing), By Application (Cancer, Genetic Disease, Cardiovascular Disease), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, Australia, South Korea, Brazil, Argentina, Mexico, South Africa, Saudi Arabia, UAE), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027” in detail along with the table of contents:
Increasing cases of genetic disorders will boost the market growth
The genetic disease segment is anticipated to expand at 12.5% CAGR from 2021 to 2027. A genetic illness is a serious health disorder caused by one or more abnormalities in the genome that surges the demand for different genetic tests for accurate and early disease diagnosis. Sickle cell anaemia, tay–sachs disease, huntington's disease are some of the genetic disorders caused among individuals across the globe due to inherited medical condition.
Favorable regulatory scenario in the European region
Europe genetic testing industry revenue was over USD 3 billion in 2020. Increasing demand for prenatal and newborn testing in the countries including UK and Germany among others to detect abnormalities at an early stage will prove advantageous for the industry progression. Advanced healthcare infrastructure, availability of leading companies as well as advanced technology integrated with genetic testing will foster the market share.
Some of the major players involved in the market are 23andMe, Inc., Abbott Laboratories, Ambry Genetics (Konica Minolta), BGI, Biocartis Group NV, Bio-Helix Co., Ltd., bioMérieux SA, Blueprint Genetics, Cepheid (Danaher Corporation), and Eurofins Scientific, among others.
Explore More on Related Topics: